INmune Bio Inc. (INMB)
| Market Cap | 34.29M |
| Revenue (ttm) | 50,000 |
| Net Income (ttm) | -49.89M |
| Shares Out | 26.59M |
| EPS (ttm) | -2.11 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 607,989 |
| Open | 1.360 |
| Previous Close | 1.340 |
| Day's Range | 1.260 - 1.370 |
| 52-Week Range | 1.210 - 11.640 |
| Beta | 0.75 |
| Analysts | Hold |
| Price Target | 4.30 (+233.33%) |
| Earnings Date | Mar 26, 2026 |
About INMB
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company’s development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatmen... [Read more]
Financial Performance
In 2024, INmune Bio's revenue was $14,000, a decrease of -90.97% compared to the previous year's $155,000. Losses were -$42.08 million, 40.2% more than in 2023.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for INMB stock is "Hold." The 12-month stock price target is $4.3, which is an increase of 233.33% from the latest price.
News
INmune Bio Inc. (INMB) Discusses XPro1595 Phase II MINDFuL Results and Registrational Strategy in Alzheimer's Disease Transcript
INmune Bio Inc. (INMB) Discusses XPro1595 Phase II MINDFuL Results and Registrational Strategy in Alzheimer's Disease Transcript
INmune Bio Inc. (INMB) Discusses MissionEB Phase III Trial and CORDStrom as a Disease-Modifying Therapy for RDEB Transcript
INmune Bio Inc. (INMB) Discusses MissionEB Phase III Trial and CORDStrom as a Disease-Modifying Therapy for RDEB Transcript
INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer's Webinar
Webinar on February 27 at 9:30 AM ET will have key opinion leaders discuss recent and upcoming clinical development of XPro1595 Webinar on February 27 at 9:30 AM ET will have key opinion leaders discu...
INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB
Clinical investigators from the trial to share real-world experience treating RDEB patients with CORDStrom and present new data from the MissionEB clinical study
INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB
Pre-submission package is a process that facilitates early feedback from the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA), designed to streamline the final approval p...
INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives
Boca Raton, FL, Jan. 27, 2026 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, presents the following letter to investors from David Moss, CEO...
Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio's CORDStrom™ Platform
Boca Raton, FL, Dec. 05, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (“INmune” or the “Company”), a clinical-stage inflammation and immunology company, announces a recently published over...
INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595's Evidence Base in High-Inflammation Alzheimer's Patients
Boca Raton, FL, Dec. 01, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage biotechnology company developing inflammation and immunology therapies targeting innate immune dysfu...
INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference
Boca Raton, FL, Nov. 18, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces two presentations at the upcoming 18th Clinical...
INmune Bio, Inc. (INMB) Q3 2025 Earnings Call Transcript
INmune Bio, Inc. ( INMB) Q3 2025 Earnings Call October 30, 2025 4:30 PM EDT Company Participants Daniel Carlson David Moss - President, CEO, Treasurer, Secretary & Director Mark Lowdell - Chief Scien...
INmune Bio Inc. Announces Third Quarter 2025 Results and Provides Business Update
BOCA RATON, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness ...
INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025
Boca Raton, FL, Oct. 14, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces that David Moss, Chief Executive Officer will p...
INmune Bio, Inc. (INMB) Q2 2025 Earnings Call Transcript
INmune Bio, Inc. (NASDAQ:INMB) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Christopher Barnum - Corporate Participant Daniel Carlson - Corporate Participant David ...
INmune Bio's CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment
BOCA RATON, FL, Aug. 04, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, is pleased to report that its Phase I/II trial ...
INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 31, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflam...
INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro™ Presented at the Alzheimer's Association International Conference
Boca Raton, July 29, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) announced today that a video detailing the additional findings from the Phase 2 MINDFuL trial evaluating XPro™, a novel sel...
INmune Bio: Thinking Through XPro's MINDFuL Data In Early Alzheimer's
INmune Bio's XPro missed its Phase II primary endpoint, but subgroup data and safety profile suggest potential for targeted Alzheimer's patients with neuroinflammation. Despite the setback, I see sign...
'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday
Former hedge fund manager Martin Shkreli has issued a stark warning on the near-term trajectory of a biotech startup, just days after it witnessed a surge.
INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Boca Raton, Florida, June 30, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, today announced that it has closed its regi...
Alzheimer's Setback Hits INmune Bio Stock, But FDA Hopes Remain
INmune Bio Inc. INMB stock is trading lower on Monday, with a session volume of 23.2 million, compared to the average volume of 1.45 million, as per data from Benzinga Pro.
INmune Bio's Alzheimer's drug fails to meet main goal in mid-stage study
INmune Bio said on Monday its experimental Alzheimer's drug failed to improve cognitive functions in patients with early stages of the mind-robbing disease in a mid-stage study, sending its shares plu...
INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer's Disease
In the Phase 2 MINDFuL trial of XPro™ in patients with early Alzheimer's Disease (AD) with biomarkers of inflammation, the modified intent-to-treat (mITT) population (n=200) did not meet the primary c...
INmune Bio: Finding Pay Dirt In Alzheimer's?
INmune Bio is working on a drug for Alzheimer's, with a critical phase 2 readout to be announced. It is unclear whether this will be positive or negative. Other potential drug candidates could help pi...
INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Boca Raton, Florida, June 27, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, today announced that it has entered into se...
INmune Bio Stock Soars Friday On Alzheimer's Treatment Hopes
INmune Bio Inc. INMB stock is trading higher on Friday, with a session volume of 10.26 million compared to the average volume of 519.5K, per data from Benzinga Pro.